Furthermore, CD6 activation of T cells promotes TCR diversity 59, while CR2-mediated complement pathway activation enhances B cell-driven activation of tumor-specific CD8+ T cells in anti-tumor immunity 60. The gene discussed is CR2; the disease is neoplasm.